Altimmune announced its Q3 2025 earnings today, reporting a net loss for the quarter ended September 30, 2025, and disclosing cash reserves of $211 million.
The announcement also highlighted key business updates, including the expected 48‑week data from the IMPACT Phase 2b MASH trial and the scheduled End‑of‑Phase 2 meeting with the FDA in Q4 2025.
Investors can find detailed financial figures and guidance on Altimmune’s investor relations website.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.